The short answer
Selank lacks methionine, cysteine, asparagine and glutamine, between them the source of methionine oxidation, disulfide scrambling and deamidation, which account for most peptide degradation in practice. What remains is hydrolysis, plus one practical difficulty: no aromatic residue means no 280 nm quantification.
Key facts
- Supplied as
- White lyophilised powder
- Disulfide risk
- None (no cysteine)
- Oxidation risk
- Low (no methionine)
- Deamidation risk
- None (no Asn or Gln)
- Main route
- Hydrolysis, resisted by three prolines
- Lyophilised storage
- Cold, dry, dark
- Freeze-thaw
- Avoid by aliquoting
The residue Selank does not have
Semax, built by the same institute using the same design method, carries a methionine at position 1, and that single residue is the whole story of its handling, because the thioether sulfur oxidises to the sulfoxide and adds 16 Da. Selank has no methionine anywhere in TKPRPGP. The degradation route that dominates guidance for Semax, and for MOTS-c with its two methionines, simply does not exist here.
Nor does it have the other two
No cysteine, so no disulfide bonds to form or scramble and no reducing agent needed in buffer. No asparagine and no glutamine, so deamidation is off the table as well. Between them, methionine oxidation, disulfide scrambling and deamidation account for most of what goes wrong with research peptides in practice. Selank is vulnerable to none of them.
Research material referenced
Selank 10mg, third-party HPLC tested
What is left to go wrong
Hydrolysis of the peptide backbone, and physical loss to container surfaces. A real concern for small quantities of a highly charged peptide, which adsorbs to glass and plastic more readily than a neutral one. Three prolines in seven residues resist enzymatic cleavage well, but proline confers no protection against simple chemical hydrolysis in solution over time. The general case for keeping lyophilised peptide cold, dry and dark is set out under bacteriostatic water; it applies here, just for a narrower set of reasons than usual.
The quantification problem
This is where Selank is harder to work with than Semax rather than easier. TKPRPGP contains no tryptophan, no tyrosine and no phenylalanine, so it has no absorbance near 280 nm. The wavelength every standard spectrophotometric peptide assay relies on. Semax has phenylalanine and histidine; DSIP has a tryptophan. Selank has nothing, and concentration has to be established by another route entirely.
Reconstitution
Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming means an air-liquid interface has been created, and that is where peptides unfold and then aggregate. Selank is small, highly charged and very hydrophilic, so it goes into solution readily; difficulty dissolving at a concentration that previously worked is therefore a more informative warning sign here than it would be for a stubborn hydrophobic peptide.
After reconstitution
Aliquot into single-use volumes. Repeated freeze-thaw cycling concentrates solutes at the advancing ice boundary and creates fresh interfaces on every cycle, and neither is addressed by the absence of oxidation-prone residues. Selank's chemical robustness protects it from specific reactions, not from physical handling damage.
Frequently asked questions
Does Selank need a reducing agent in buffer?
No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.
Is Selank less light-sensitive than other peptides?
It lacks the methionine whose photo-accelerated oxidation drives that concern elsewhere. Dark storage remains sensible practice but the specific liability is absent.
Why avoid shaking the vial?
Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence. Swirl instead.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Selank (Tuftsin Analogue) articles
- Selank in the Published LiteratureAbout 135 indexed PubMed records, against 690 for its parent peptide tuftsin. How the mechanistic and clinical literatures split, and how to read them.
- What Is Selank? Sequence, Origin and Enkephalin MechanismSelank is a synthetic heptapeptide built from tuftsin with a Pro-Gly-Pro extension. Structure, enkephalin mechanism, regulatory status and the evidence base.
- Selank's Enkephalinase MechanismSelank does not bind opioid receptors. Reported work shows it inhibits enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins.
- Selank and GABAergic SignallingSelank has been reported to affect GABA-A receptor expression without binding the receptor directly - a different mechanism from benzodiazepines.